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isolated data3: (1) Most of the events were observed during or
after CPB. (2) Many cases were associated with the use of the
curare alcuronium. (3) Some cases were observed under
usual anesthesia with etomidate, fentanyl, pancuronium, and
diazepam. (4) Some cases were clearly associated with prot-
amine infusion. (5) At least in one case the vasodilatation was
induced after heparin infusion. (6) The vasoplegia was also
observed in noncardiac operations. (7) Our impression was
that the syndrome happened periodically. (8) Many patients
had diabetes. (9) Many patients were previously using the
calcium antagonist diltiazem. To these observations we can
add the possible effects of the angiotensin-converting enzyme
inhibitors as suggested by Tuman and associates4 and men-
tioned by Yiu, Robin, and Pattison.1
We also have used methylene blue to treat anaphylaxis.
Our cumulative clinical experience includes 6 patients. The
causes were iodinate radiographic contrast material (5
patients) and penicillin (1 patient). The traditional treatments
(high doses of epinephrine and corticosteroids) failed to
reverse the cardiocirculatory collapse, urticaria, and
angioedema. Four patients were treated by a bolus infusion
of 4% methylene blue, 1.5 mg/kg (120 mg), followed by
continuous infusion of another 120 mg diluted in 5% glucose
in water. The infusion was administered as a bolus because
of the severity of shock. Two patients received only continu-
ous infusion during 30 to 40 minutes. The anaphylactic man-
ifestations were completely reversed in 10 to 15 minutes. In
1 patient we observed nodal cardiac rhythm over 1 minute
during the infusion of the dye, which reversed spontaneous-
ly. One hypertensive patient had angina pectoris during infu-
sion, without any electrocardiographic manifestation, and
did not require coronary vasodilators to reverse the symp-
toms. We obtained the hemodynamic registers of 2 patients
who had anaphylactic shock caused by radiographic contrast
material in the cardiovascular catheterization laboratory.
Cumulative experience would indicate that this dye is the
treatment of choice or an alternative to the treatment of dis-
tributive circulatory shock. I am reporting, probably, the first
experience treating anaphylaxis in human beings with meth-
ylene blue, and it deserves wide circulation because it is a
lifesaving choice.5
Nitric oxide stimulates soluble guanylate cyclase and acti-
vates the production of cyclic guanosine 3´,5´monophos-
phate (cGMP), resulting in relaxation. Inhibition of nitric
oxide synthesis is not approved for clinical use because of
the lack of specificity to the inducible form of nitric oxide
synthase and its association with tissue necrosis. Methylene
blue inhibits guanylate cyclase, avoiding the cGMP-depen-
dent vasorelaxant effect of nitric oxide in the smooth muscle
of the vessels. Also, thiazine dye is widely used in clinical
medicine to reduce methemoglobin, to treat malaria, and to
cleanse the urinary tract. Otherwise, methylene blue is not
associated with tissue necrosis, as caused by nitric oxide
synthase inhibition, and its lethal dose is more than 40
mg/kg, as shown experimentally in sheep. Myles, Leong,
and Curry6 failed to identify an increase in nitric oxide
release after, or as a consequence of, CPB on the basis of the
serum and urine nitrite/nitrate levels. Since methylene blue
blocks the soluble guanylate cyclase, which is the final effect
on the nitric oxide pathway, it is hard to determine a differ-
ent cGMP-dependent mechanism, and the hypothesis of
direct activation of this final common pathway of nitric
oxide release is very improbable. I guess it is more logical to
speculate on the existence of another non-nitric cGMP-
dependent pathway, with different receptors and/or different
G-proteins, or else a sensitization of vascular smooth muscle
cells to the action of nitric oxide, as hypothesized by Yiu,
Robin, and Pattison.1
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Reply to the Editor:
We thank Evora for adding his experience with methylene
blue. In most instances of low systemic vascular resistance
(SVR) syndrome necessitating pharmacologic intervention,
vasopressor therapy over a number of hours is limited. Thus
whether methylene blue should be the drug of choice is
speculative at this stage. Nevertheless, in cases in which
first-line therapy has failed, the dramatic success and long-
lasting effect of this drug that we found in our case, and that
Evora and his colleagues presumably found as well, are cer-
tainly impressive. This leads us to propose that early use of
methylene blue may halt the progression of low SVR even
in patients responsive to norepinephrine and mitigate the
need for a protracted course of vasoconstrictor use. A ran-
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domized clinical study to evaluate this hypothesis is justi-
fiable.
Patrick Yiu, FRCS
Cardiothoracic Surgical Unit
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Combined mitral valve repair and the Cox maze
procedure for mitral valve prolapse and regurgi-
tation and associated atrial fibrillation
To the Editor:
I read with great interest the report by Handa and associ-
ates1 on the early and intermediate term results of combined
mitral valve repair and the Cox maze procedure for patients
with severe mitral regurgitation and associated atrial fibrilla-
tion. It is gratifying to note that at the Mayo Clinic the addi-
tion of the Cox maze procedure to mitral valve repair not only
is safe and effective but also decreases late complications.
One of the serious complications of mitral valve prolapse,
which is otherwise a common2 and benign3 condition, is
mitral regurgitation.4,5 In fact, the commonest cause of mitral
regurgitation in the United States is mitral valve prolapse.5,6
Mitral regurgitation in mitral valve prolapse may become
progressive in some patients.5 One of the serious complica-
tions of progressive mitral regurgitation is atrial fibrillation,
which usually persists even after successful corrective
surgery of the mitral valve and often recurs after pharmaco-
logic or electric cardioversion. Although postoperative atrial
fibrillation can be successfully managed by antiarrhythmic
drugs and long-term anticoagulant therapy to prevent throm-
boembolism, these therapeutic modalities are not without
side-effects, torsades de pointes and bleeding, respectively. It
is gratifying that the adjunctive Cox maze procedure at the
Mayo Clinic increased the restoration of sinus rhythm to 82%
of their patients.
Therefore, as the authors concluded, “Although the addi-
tion of the Cox maze procedure lengthens hospital stay in
patients having mitral valve repair, overall medical costs may
be decreased by reducing the need for long-term anticoagula-
tion, as well as costs associated with stroke and bleeding
complications.”1
Tsung O. Cheng, MD
Professor of Medicine
The George Washington University
Washington, DC 20037
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Should the bidirectional Glenn procedure be better
performed through the support of cardiopulmonary
bypass?
To the Editor:
We read with great interest the report of Jahangiri and asso-
ciates1 and the commentary by Jonas on the technique of bidi-
rectional Glenn shunt through a thoracotomy without the use
of cardiopulmonary bypass (CPB). We agree that clamping
the superior vena cava (SVC) without decompressing the
internal jugular system exposes the brain to the effects of
reduced cerebral perfusion pressure. We have used electro-
physiological indices of cerebral function (electroen-
cephalography or evoked potentials) and transcranial Doppler
during bidirectional Glenn shunts in patients with pulmonary
atresia without support (n = 2) or through the use of CPB (n
= 4). During clamping of the SVC without CPB, major reduc-
tions (>50%) in the diastolic, mean, and peak systolic blood
flow velocities of the middle cerebral artery were identified,
which were followed by mild electrocortical alterations as
indicated by longer latencies of the cortically generated
evoked potentials.2 In contrast, this situation did not occur or
was minimal in those cases in which clamping of the SVC
was done with the support of CPB. We have learned that
Doppler flow changes and electrocortical alterations may be
expected as a result of acute SVC hypertension if the internal
jugular venous system is not decompressed.3 In one of our
cases without CPB, an intraoperative shunt into the SVC was
indicated due to the presence of extremely low flow veloci-
ties and electrocortical alterations during SVC clamping. In
this case, while the SVC shunt was patent, flow velocities
were maintained and the latencies of evoked potentials
returned to preclamping levels.4 In our institution, we rou-
tinely use CPB and intraoperative brain function monitoring
by transcranial Doppler, near-infrared spectrophotometry,
and electroencephalography for children undergoing these
procedures.3 A note of caution should be made that the
reported absence of gross neurologic deficits in Jahangiri and
colleagues’ cases is not an indicator that the brain is free of
potential alterations during SVC clamping without CPB.
Furthermore, under conditions of normothermic ischemia,
the brain does not receive the protective benefit of hypother-
mia.5 Without brain protection, even short intervals of low
cerebral perfusion could generate minor or subclinical
deficits that might be detectable only through detailed cogni-
tive testing. We agree with Jonas’ comments that the demon-
stration of safety of this procedure will rest on the careful
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